Epilepsy

This approval marks the first and only oral film approved by the FDA for the treatment of seizures associated with Lennox-Gastaut syndrome.

In absence of head-to-head trials between 2nd and 3rd generation antiepileptic drugs, a meta-analysis was used to identify suitable agents for monotherapy.

Other risk factors included the age of conception, with women younger than 18 or older than 37 being at greatest risk.

Switching antiepileptic drug manufacturer was found to increase the risk of seizure recurrence in a German population, contrary to findings in the US.

The effect of a carbapenem on VPA is significant and may result in reduced efficacy and increased seizure activity. Because of the mechanism of this interaction, increasing the dose of the VPA will unlikely achieve therapeutic plasma concentrations.

Investigators used EHR data to identify epilepsy patients at risk for obstructive sleep apnea and refer them for polysomnography.

Outcomes can worsen for pregnant women with epilepsy when antiepileptic drug concentrations fall below 65% of preconception amounts.

Perampanel (FYCOMPA) has been approved for patients aged 4 years or older, who suffer from partial-onset seizures with or without secondarily generalized seizures, as both a tablet and oral suspension formulation.

Bridge the Gap – SYNGAP Education and Research Foundation presented Texas Children’s Hospital with their first research grant of $25,000.

The FDA has granted a tentative approval to Aquestive Therapeutics, Inc.’s clobazam (Sympazan) oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older.

Stem cell research from the University of Michigan reveals dangerous cardiac effects of a gene mutation in patients with Dravet syndrome.

Stiripentol (Diacomit) has been approved for treatment in patients 2 years of age and older with Dravet syndrome, a rare form of epilepsy.

The FDA has approved stiripentol (Diacomit) for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy.

If approved in early 2019, the nasal spray would become the first approved therapy indicated for seizure clusters in 17 years.

Holidays and special events can cause increased likelihood of status epilepticus, possibly due to alcohol consumption and withdrawal, changes in sleep patterns, and non-compliance with anti-seizure drugs.

The phase 3 trial evaluating ZX008 as a treatment for Dravet syndrome met its primary endpoint.

The newly-revealed structure of the neurotransmitter GABAA, a γ-aminobutyric acid, opens new possibilities for drugs to treat epilepsy, anxiety, and insomnia.

Converting from brand-name levetiracetam to generic version does not greatly increase seizure frequency among patients with epilepsy.

Cannabidiol (Epidiolex) is the first drug containing a marijuana-derived substance to receive FDA approval.

The new findings also show that the premature activation of synapses can be prevented by AMPA receptor antagonist therapy.

The supplemental New Drug Application for perampanel (Fycompa) expands the indication to include pediatric patients 2-12 years of age.

The zEEG provides clinicians and patients with an EEG system that is simple, easy and convenient that benefits with a quick and smart analysis of data through a cloud platform.

The FDA will come to a conclusion on whether to approve Epidiolex in late June and if approved, this will be the first cannabis-based product to become FDA approved.

Approval provides pediatric epilepsy patients a treatment option to be administered at a therapeutic dose from day 1/

EpiFinder, a mobile health application, predicted either an epilepsy syndrome or alternative diagnosis with 86.8% accuracy.